What one share of Abivax S.A. holds
We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies.
Abivax S.A.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$5.47 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.62 |
| Cash and investments | $7.72 |
| Book value | $6.80 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$3.25 | $0.00 | −$3.45 | — | $1.75 |
| 2022 | — | −$3.35 | $0.02 | −$2.99 | — | $0.34 |
| 2023 | — | −$3.71 | $0.01 | −$2.45 | — | $3.45 |
| 2024 | — | −$3.02 | $0.01 | −$2.66 | — | $0.66 |
| 2025 | — | −$5.47 | $0.00 | −$2.62 | — | $6.80 |
Common questions about Abivax S.A.
How much does one share of Abivax S.A. earn?
Over its latest fiscal year, Abivax S.A. lost $5.47 for each share.
Does Abivax S.A. pay a dividend?
Abivax S.A. didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Abivax S.A.’s book value per share?
Abivax S.A.’s book value is $6.80 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Abivax S.A. have?
Each share of Abivax S.A. has $7.72 of cash and investments, as of December 31, 2025.
What is Abivax S.A.’s free cash flow per share?
−$2.62 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Abivax S.A. bought back shares?
Abivax S.A.’s share count rose about 350% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.